Pathway analysis tools for personalized medicine and drug repositioning
Award amount
$1,760,436Program and phase
SBIR · Phase IIAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ADVAITA CORP
- Proposal award date
- 2014-05-01
- Contract end date
- 2018-04-30
- UEI
- Q81XNNYPK5H3
- Solicitation number
- PAR09-220
- Topic code
- 300
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A web-based platform for robust single-cell analysis, bulk data deconvolution and system-level analysis
- SBIR Phase I: A knowledge base and drug repurposing platform for COVID-19
- SBIR Phase II: A multi-omics data integration approach for precision medicine and improved clinical trial success
- SBIR Phase I: A multi-omics data integration approach for precision medicine and improved clinical trial success
- Increasing the efficacy of MTI-101 in MM using Ab conjugation strategies
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
- Combinatorial pipeline for discovery of anti-GPCR Nanobodies
- Development of a GBP-based glycosylation analysis system
- Extended-release injectable gel for multi-day treatment of postoperative pain
- eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening
Research funding history
8 SBIR/STTR records share this UEI (2009–2023). Reported award amounts total $7,254,780. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services, National Science Foundation